亿帆医药（002019）：创新药主业稳健发展，泛酸钙价格处周期底部

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of 17.40 CNY per share for the next six months [3]. Core Insights - The company is focused on "innovation and internationalization" as part of its long-term development strategy, leading to a stable growth in its core business and a rich pipeline of innovative drugs [1]. - The core product, Vitamin B5 (Calcium Pantothenate), is currently priced at 41.50 CNY/kg, which is at the historical bottom of the past decade, indicating limited downside risk and potential for price improvement [2]. - The company is expected to achieve net profits of 603 million CNY, 701 million CNY, and 803 million CNY for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 56.1%, 16.3%, and 14.6% [3]. Financial Summary - The company’s projected revenues for 2025, 2026, and 2027 are 5.961 billion CNY, 6.779 billion CNY, and 7.586 billion CNY, respectively, with a revenue growth rate of 15.5% in 2025 and 13.7% in 2026 [4][8]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.50 CNY, 0.58 CNY, and 0.66 CNY, respectively, with a price-to-earnings (PE) ratio of 30 times for 2026 [3][4]. - The net profit margin is projected to improve from 10.1% in 2025 to 10.6% in 2027, indicating a positive trend in profitability [4].